Forschungs- & Entwicklungsinformationsdienst der Gemeinschaft - CORDIS

FP6

INGENIOUS HYPERCARE Berichtzusammenfassung

Project ID: 37093
Gefördert unter: FP6-LIFESCIHEALTH
Land: Italy

Final Report Summary - INGENIOUS HYPERCARE (Integrated Genomics, Clinical Research and Care in Hypertension)

A better prevention of hypertension and hypertension-related cardiovascular events is an essential public health goal in Europe, where cardiovascular diseases are the major cause of mortality and morbidity. Despite the widely shared opinion that hypertension has an important hereditary component, genetic and genomic research has not yet been fully exploited by medical research on hypertension, which has limited progress toward primary prevention of hypertension, and prevention of the cardiac, vascular and renal consequences of hypertension.

The problem has been approached by integrating complementary but still fragmented experience in the mechanisms of blood pressure control and hypertension development, in phenotyping initiation and progression of organ damage and in exploring genetics, genomics and proteomics of proneness to hypertension and hypertension-related cardiovascular disease.

The strategic objective of the INGENIOUS HYPERCARE Network of Excellence (NoE), was the integration of 31 research teams (including one Small and medium enterprises (SMEs)) working on genetics, functional genomics and molecular mechanisms of hypertension and hypertension-related cardiac and vascular damage and one SME experienced in European Commission (EC) project management, in 11 European Union (EU) Member States, one Associated State (Switzerland), and two countries having Science and Technology cooperation agreements with EU (Russian Federation and China) by integrating complementary but still fragmented experiences in studying the physiological mechanisms of blood pressure control and hypertension development, in phenotyping initiation and progression of organ damage and in exploring genetics, genomics and proteomics of hypertension-related disease.

A powerful instrument of integration had been the programme of joint research activities. A first group of three research packages addressed Mechanomics of Hypertension, i.e. identifying genetic, genomic and proteomic markers of disturbances in the major mechanisms controlling blood pressure (autonomic control, inflammation and oxidative stress, renal sodium handling), as indicators of the risk of becoming hypertensive, and of yet unknown pathways facilitating the development of hypertension. The second group of three research packages addressed mechanomics of hypertension-related diseases, i.e. identifying genetic, genomic and proteomic markers of the risk of developing a hypertension-related event (stroke, renal dysfunction, heart failure), as well as unknown mechanisms mediating transition from a risk factor to disease. Spreading of excellence beyond the Network had been done with the support of the European Society of Hypertension, that was involved as the network advisory board.

Furthermore, in order to facilitate this integration, to enhance scientific productivity and to create durable instruments of collaboration extending beyond the terms of the EC contract, collaborative research platforms had been established for phenotyping, genotyping, proteomic and animal research. Finally, an indispensable instrument of integration had been the early establishment of a network website (please see http://www.hypercare.eu online) with a public part (information on partners, public presentations by partners) and a confidential one, accessible by personalized passwords, with protocols and electronic case report files.

Verwandte Informationen

Kontakt

Alberto ZANCHETTI, (Scientific Director)
Tel.: +39-026-19112894
Fax: +39-025-5187506
E-Mail-Adresse
Folgen Sie uns auf: RSS Facebook Twitter YouTube Verwaltet vom Amt für Veröffentlichungen der EU Nach oben